Featured Story | By Nick Paul Taylor Progenity has begun a phase 1 clinical trial of its ingestible and self-guided drug delivery device. The study will assess the device’s gastrointestinal tolerability and ability to deliver a payload to the colon. read more |
| |
|---|
|
Top Stories By Nick Paul Taylor A nasally delivered SARS-CoV-2 fusion inhibitor has stopped the spread of the coronavirus in animals. The preclinical findings offer encouragement ahead of the generation of data on the effect of the spray on humans. read more By Nick Paul Taylor Almirall has secured exclusive rights to commercialize Wynzora for the treatment of plaque psoriasis in Europe from MC2 Therapeutics. The agreement is worth up to €15 million ($18 million) in upfront to launch payments to MC2, with “significant” sales milestones to follow if the drug hits the market. read more By Nick Paul Taylor Dr. Reddy’s Laboratories has introduced an orally disintegrating formulation of lansoprazole to the U.S. market. The new product is the therapeutic equivalent of the Prevacid SoluTab delayed-release tablets sold by Takeda. read more By Angus Liu Scientists at China’s National center for Nanoscience and Technology have designed a hydrogel to deliver an mRNA vaccine with an immune-stimulating adjuvant. When injected into mice with melanoma, the vaccine stayed active for at least 30 days, inhibiting tumor growth and preventing metastasis. read more By Beth Snyder Bulik,Angus Liu Fierce Pharma rounds up the top 10 of who’s who in anticipated drug launches for 2021, ranked by Evaluate consensus sales estimates for global sales in 2026. read more Resources Sponsored By: Oracle Health Sciences New research indicates an accelerated adoption of decentralized clinical trials due to COVID-19. Sponsored By: Within3 We enable virtual work — offering over-time sessions where participants are more focused, insights are more diverse and business goals are met. Sponsored by: Catalent Discover the current state of patient-focused dose design through clinical evidence, real-world case studies and patient preference-driven drug design solutions that can help develop better treatments and successful real-world outcomes. Sponsored by: Catalent This eBook features insights from experts in the industry on patient-centric drug development challenges and strategies on advancing drug design and development effectively. Sponsored By: Medidata, a Dassault Systèmes company 8 parameters to optimize your “Path to Virtualization” across site- and patient-centric capabilities in this Sponsor Edition eBook. Sponsored By: LabVantage Solutions Uncover the real impact of “digital transformation” with practical advice to help you plan your own transformative journey to a harmonized digital ecosystem. Sponsored By: Acorn AI, a Medidata Company Acorn AI has developed a flexible and scalable Commercial Data Model that provides pharmaceutical companies with the data-driven insights required to respond to the industry’s ever-changing landscape. Download the whitepaper to learn how Acorn AI’s intuitive data model enables launch success and more. Sponsored by: Catalent Learn about drug product process development challenges and risks, the difference between innovator and biosimilar drug product process development, and more during the drug product process development phase. Sponsored by: Catalent In this webinar, pharmaceutical scientists present real-life examples of challenges they’ve overcome in the transfer of oral small molecules from a dedicated early-phase development site to a dedicated late-phase manufacturing site. | 
